This article addresses the Core Competency of dumps. feelings fade fast getting together with friends for an activity, feelings of guilt. She acknowledged that she could still enjoy damn depression coming back again, in interview, she reported feeling care physician). second at age 26 (remitted with citalopram from her primary therapy provided through campus counseling services) and a at a large university (remitted with cognitive-behavioral missions: one at age 20 during her sophomore year in college said when she noticed that she felt fatigued most days, “I’ve been struggling with this depression for months, and nothing seems to be helping this time around,“ the patient said when she first met you. Brenda reported two previous lifetime episodes of major depression, both with clear remissions: one at age 20 during her sophomore year in college at a large university (remitted with cognitive-behavioral therapy provided through campus counseling services) and a second at age 26 (remitted with citalopram from her primary care physician). “This time, it began with trouble sleeping, like it always does,” she said, “and then there was the anxiety, the pacing and fidgeting, and the crying.” She further revealed that she was experiencing decreased appetite and enough weight loss that her clothing all “felt baggy.” In your interview, she reported feeling “like I’m a loser, with this damn depression coming back again,” but denied having feelings of guilt. She acknowledged that she could still enjoy getting together with friends for an activity, “but the good feelings fade fast—a few hours later and I’m back down in the dumps.” She noted that she felt fatigued most days, “but with only a few hours of sleep a night, who wouldn’t?” She denied having suicidal thoughts or plans, adding, “I had a friend in college who overdosed on some pills, and she ended up needing a liver transplant. I would never want to inflict that on my family and friends.”

Consideration Point A. At this point in the assessment of the patient’s history, your differential diagnosis includes current
A.1 Unipolar major depressive disorder
A.2 Depression as a part of bipolar disorder
A.3 Attention-deficit hyperactivity disorder
A.4 Substance-induced mood disorder
A.5 Generalized anxiety disorder

Case Vignette Continues
As you asked more questions about Brenda’s current episode, you learned that concentrating at work was difficult for her. She was lead Web designer for a local TV station’s online presence and reported it was challenging to keep the site up to date with the latest news. “It’s pretty noisy in here,” she said, tapping her head, “with worries about ‘am I doing this right?’ ‘did I forget something?’ ‘did I check these details?’ and on and on and on. It’s exhausting! It’s really hard to stay focused on the present.” In response to your question about what things may relieve her symptoms, she volunteered, “When I was in college, I tried to use marijuana and alcohol to calm myself down, but the weed made me too stoned to do well in class, and a couple of hours of being buzzed with alcohol was never worth it. And I didn’t want to go down that road, like my mother’s brother. He was in and out of rehab when I was a kid, and that messed up my cousins.” She confirmed that she would limit herself to one drink when getting together with friends, imbibing maybe twice a month, and she did not smoke marijuana or tobacco at present. She denied using any other substances.

Brenda denied ever having racing thoughts, a reduced need for sleep, periods of excessive goal-directed activity, or engagement in high-risk behaviors. She acknowledged that “sometimes I’m more creative than other times, but it’s just like a day of being ‘in the zone’ when the ideas flow effortlessly,
and then on other days it can take forever to come up with something new and different."

During the current episode, Brenda and her primary care physician had first tried citalopram; the final dose attained was 40 mg/day for eight weeks without any real symptomatic relief or changes on the ECGs done by her primary care physician. They then had tried sertraline and got to 100 mg/day for 12 weeks before Brenda was referred to you. She tolerated both medications adequately, with minimal gastrointestinal upset when first starting out and some reduction in libido.

When you asked about Brenda’s lifetime history, you learned that she was “pretty anxious” in social settings as a child, “but my parents pushed me to join the debate team in junior high and high school, and that helped me learn not to be so anxious when people are watching.” She denied having gastrointestinal discomfort, sweaty palms, racing pulse, or other panic symptoms when being watched by others. Aside from her anxious worries, she denied experiencing other intrusive thoughts, hallucinations, compulsive rituals, or obsessions. She also denied having problems in childhood with interrupting others, waiting to take turns, climbing on furniture, concentrating at school, acting impulsively, or having difficulty listening to instructions or organizing tasks; if anything, she said, she had been well organized and effective in activities throughout her life, except during the periods of depression.

When recounting her medical history, the patient denied having major medical conditions. During your evaluation, Brenda reported taking sertraline at 100 mg/day and oral contraceptive pills.

Brenda had learned during a prior depressive episode to self-monitor her symptoms with the nine-item Patient Health Questionnaire (PHQ-9) (1) and brought in a spreadsheet graph showing that her symptoms had not varied much with either prior medication trial, although her score had improved slightly, from 19 prior to starting sertraline to 16. Still, her score was indicative of a moderately severe symptom burden.

Brenda was pleasant and cooperative with the interview, casually attired in a dress with bold colors. Mild psychomotor agitation was noted during the evaluation, as she crossed and uncrossed her legs and fidgeted with her hands. Eye contact was adequate. Speech was of a normal rate, with some monotonous prosody but at normal volume. Affect was fatigued and drained. She characterized her mood as “pretty sad today.” Her thought process was generally linear and coherent. Her thought content was without hallucinations, delusions, or current suicidal or homicidal intent. Cognitively, she was currently good, in that she was open to considering all options for treatment despite the failure of recent treatment trials to help. Neurologically, her gait, arm swing, turning, stride length, and rapidly alternating movements were all normal. You detected no focal neurological deficits.

**Consideration Point B.** Given all of these details, your next therapeutic recommendation or recommendations are

B.1. Increase the dose of sertraline to 150 or 200 mg/day
B.2. Switch to another agent, such as vortioxetine
B.3. Augment her regimen with lithium
B.4. Start electroconvulsive therapy

**Case Vignette Continues**

In your discussion of the treatment options, the patient expressed that the most acceptable option to her was a trial of a higher dose of sertraline, rather than adding or switching to something new. You and Brenda agreed to increase her dose to 150 mg/day for two weeks and then go to 200 mg/day, as tolerated.

She returned for follow-up after two and four weeks and reported that she had experienced some clearer improvement in symptoms (less crying, better sleep) but was still experiencing a lot of inner agitation and anxiety. Her PHQ-9 score has decreased to 10.

Brenda was open to hearing your recommendations for modifications to the treatment plan, as she was still experiencing moderate symptom burden and trouble functioning at work.

**Consideration Point C.** Given all the details of the case, your next therapeutic recommendation or recommendations are

C.1. Augment with lithium
C.2. Augment with a second-generation antipsychotic, such as aripiprazole
C.3. Augment with mindfulness-based cognitive therapy (MBCT)
C.4. Augment with repetitive transcranial magnetic stimulation (rTMS)

**Case Vignette Concludes**

The patient was most interested in options that involved adding a nonpharmacologic treatment, given her past and current experiences with medication. Brenda had read a lot about rTMS online but believed she would not be able to take time off from work during the day to travel to the nearest center for treatment: “It sounds good, but I just can’t be gone from work that much—I’m already working from early morning ‘til nighttime because ‘news happens,’ as we say at the station.” She thought that MBCT resonated better with what she perceived as her issues with “a busy mind, sad thoughts, and worries about the future and past.” You referred her to an MBCT therapist who ran an evening group
on Sundays, which fit well with the patient’s weekly schedule. She continued sertraline at 200 mg/day.

The patient reported by phone after two weeks of MBCT that her symptoms had continued to decrease, and at an in-office visit after four weeks of therapy, her PHQ-9 score had declined to 6. After completing the eight-week course of MBCT group therapy, Brenda reported, “I’m myself again,” and she was eager to continue work with you to prevent a recurrence. “I’ve read about recurrence online; I am not thrilled with this, but the odds seem pretty strong that I’ll have another episode at some point, and I’d like to do a lot of living before that happens.” You reinforced the value of her own observation that sleep disturbance had been an early symptom in all three of her episodes and reminded her of her skills with self-monitoring using the PHQ-9. You discussed the value of MBCT practices in preventing relapse and the available data about maintenance medication. You scheduled her for a follow-up visit in three months with the understanding that she could always call for an earlier appointment if her symptoms started to return.

Answers: Scoring, Relative Weights, and Comments

Consideration Point A

A.1.______(+3) Unipolar major depressive disorder. The patient endorsed several of the DSM-5 criteria for major depressive disorder (2).

A.2.______(+3) Depression as part of bipolar disorder. Her depressive episode could be part of unipolar or bipolar mood disorder (2).

A.3.______(+1) Attention-deficit hyperactivity disorder. Although she endorsed some trouble with concentration, that phenomenon is transdiagnostic. The bulk of the information is more supportive of other conditions, although some elements of her childhood have not yet been explored (2).

A.4.______(+3) Substance-induced mood disorder. You have not yet elicited data to support or refute this possibility and so should continue to consider it (2).

A.5.______(+3) Generalized anxiety disorder. Although generalized anxiety disorder can co-occur with mood disorders, more information is needed before any conclusions can be reached about an independent diagnosis of generalized anxiety disorder (2).

Consideration Point B

B.1.______(+3) Increase the dose of sertraline to 150 or 200 mg/day. The dose in the patient’s sertraline trial has not yet been optimized by pushing to a higher but tolerated dose. Work from the Improving Mood–Promoting Access to Collaborative Treatment program and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial both support dose optimization as a tactic (3–5). Patient preference is a key consideration.

B.2.______(+1) Switch to another agent, such as vortioxetine. Switching to another medication is supported by the American Psychiatric Association evidence-based guidelines as a possibility (3). However, the trial of sertraline is inconclusive as to efficacy and, if a medication is adequately tolerated, many patients and clinicians prefer to optimize the dose before abandoning a partially effective drug. Patient preference is a key consideration.

B.3.______(+1) Augment regimen with lithium. Lithium augmentation was found to be useful in the STAR*D trial (6), but, as with a switch to another agent, many patients and clinicians prefer to optimize the dose of an antidepressant before adding a new agent that may bring new side effects. Again, patient preference is a key consideration.

B.4.______(−3) Start electroconvulsive therapy. Although electroconvulsive therapy is an evidence-based practice for the treatment of depression, it is not the usual next step in the treatment algorithm for a patient like this, with depression that has not been adequately treated with pharmacotherapy (3, 7).

Consideration Point C

C.1.______(+1) Augment with lithium. As above, augmentation with lithium is supported by evidence, but patients may associate this medication with stigma or side effects.

C.2.______(+1) Augment with a second-generation antipsychotic, such as aripiprazole. The U.S. Food and Drug Administration has approved some second-generation antipsychotic agents, such as aripiprazole, for use as an adjunctive treatment in depression (8).

C.3.______(+3) Augment with mindfulness-based cognitive therapy (MBCT). Some evidence has suggested that psychotherapies, such as MBCT, may be useful in addressing residual symptoms and in preventing relapse in major depressive disorder (9). Treatment options should acknowledge and address a patient’s priorities.

C.4.______(+1) Augment with repetitive transcranial magnetic stimulation (rTMS). The U.S. Food and Drug Administration has approved rTMS as a primary (monotherapy) treatment in major depressive disorder (3, 7); rTMS has subsequently been examined as an adjunctive treatment (10).

Your Total

<table>
<thead>
<tr>
<th>Consideration Point</th>
<th>Score</th>
<th>Ideal Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>24</td>
<td></td>
</tr>
</tbody>
</table>
AUTHOR AND ARTICLE INFORMATION

Dr. Cook is currently on leave from the Department of Psychiatry and Biobehavioral Sciences of the David Geffen School of Medicine; the Semel Institute for Neuroscience and Human Behavior; and the Department of Bioengineering, University of California, Los Angeles (e-mail: icook@ucla.edu).

Dr. Cook reports that his active biomedical device patents are assigned to the University of California. He has been granted stock options in NeuroSigma, the licensee of some of his inventions, and he currently serves as its chief medical officer and senior vice president. From 1994 to 2008, he served on the Steering Committee on Practice Guidelines of the American Psychiatric Association, and from 2002 to 2008 he served on its executive committee.

Focus 2016; 14:210–213; doi: 10.1176/appi.focus.20150047

REFERENCES